0.611
price up icon0.07%   0.0004
after-market After Hours: .61 -0.001 -0.16%
loading
BiomX Inc stock is traded at $0.611, with a volume of 32,011. It is up +0.07% in the last 24 hours and up +4.48% over the past month. BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$0.6106
Open:
$0.6331
24h Volume:
32,011
Relative Volume:
0.29
Market Cap:
$13.63M
Revenue:
-
Net Income/Loss:
$-26.56M
P/E Ratio:
-0.94
EPS:
-0.65
Net Cash Flow:
$-22.29M
1W Performance:
+13.21%
1M Performance:
+4.48%
6M Performance:
-30.56%
1Y Performance:
-81.82%
1-Day Range:
Value
$0.61
$0.6331
1-Week Range:
Value
$0.5201
$0.6331
52-Week Range:
Value
$0.477
$4.99

BiomX Inc Stock (PHGE) Company Profile

Name
Name
BiomX Inc
Name
Phone
972 7 23942377
Name
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Name
Employee
73
Name
Twitter
@BiomX_Inc
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
PHGE's Discussions on Twitter

Compare PHGE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PHGE
BiomX Inc
0.611 13.63M 0 -26.56M -22.29M -0.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

BiomX Inc Stock (PHGE) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-21 Initiated Ladenburg Thalmann Buy

BiomX Inc Stock (PHGE) Latest News

pulisher
Apr 19, 2025

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN

Apr 19, 2025
pulisher
Apr 06, 2025

HC Wainwright Reiterates “Buy” Rating for BiomX (NYSEMKT:PHGE) - Defense World

Apr 06, 2025
pulisher
Apr 04, 2025

Q1 Earnings Estimate for BiomX Issued By HC Wainwright - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

What is HC Wainwright’s Estimate for BiomX FY2025 Earnings? - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

What is HC Wainwright’s Forecast for BiomX Q1 Earnings? - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 01, 2025

Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Biomx stock plunges to 52-week low, hits $0.48 - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India

Apr 01, 2025
pulisher
Mar 31, 2025

BiomX Announces Positive Phase 2 Trial Results - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX reports progress in diabetic ulcer treatment - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

Phage Therapy Market Know the Scope and Trends - openPR

Mar 27, 2025
pulisher
Mar 26, 2025

BiomX (PHGE) Expected to Announce Earnings on Wednesday - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

BiomX Inc Reports Q4 2024 EPS of -$2.56, Revenue at $0.00 Millio - GuruFocus

Mar 25, 2025
pulisher
Mar 25, 2025

BiomX Inc. Secures $12 Million in Financing to Advance Clinical Trials for BX004 and BX211 - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings Scheduled For March 25, 2025 - Benzinga

Mar 25, 2025
pulisher
Mar 20, 2025

BiomX (PHGE) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

BiomX Inc. to Report Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 19, 2025
pulisher
Mar 09, 2025

BiomX’s $12 Million Financing - Global Legal Chronicle

Mar 09, 2025
pulisher
Mar 05, 2025

BiomX Inc. secures $12 million from recent offerings - Investing.com India

Mar 05, 2025
pulisher
Mar 04, 2025

Biomx raises $12M to advance phage therapy for CF infections - Cystic Fibrosis News Today

Mar 04, 2025
pulisher
Feb 27, 2025

BiomX Announces $12M Funding for BX004 Study - TipRanks

Feb 27, 2025
pulisher
Feb 26, 2025

BiomX announces series of financings for aggregate gross proceeds of $12M - MSN

Feb 26, 2025
pulisher
Feb 26, 2025

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can BiomX's $12M Financing Push Its Cystic Fibrosis Treatment to the Finish Line? - StockTitan

Feb 26, 2025
pulisher
Feb 18, 2025

BiomX (NYSEMKT:PHGE) Trading Up 22.3% – Still a Buy? - Defense World

Feb 18, 2025

BiomX Inc Stock (PHGE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):